JP2011520900A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520900A5
JP2011520900A5 JP2011509662A JP2011509662A JP2011520900A5 JP 2011520900 A5 JP2011520900 A5 JP 2011520900A5 JP 2011509662 A JP2011509662 A JP 2011509662A JP 2011509662 A JP2011509662 A JP 2011509662A JP 2011520900 A5 JP2011520900 A5 JP 2011520900A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
epilepsy
episode
psd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509662A
Other languages
English (en)
Japanese (ja)
Other versions
JP6005357B2 (ja
JP2011520900A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/043831 external-priority patent/WO2009140416A2/en
Publication of JP2011520900A publication Critical patent/JP2011520900A/ja
Publication of JP2011520900A5 publication Critical patent/JP2011520900A5/ja
Application granted granted Critical
Publication of JP6005357B2 publication Critical patent/JP6005357B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509662A 2008-05-16 2009-05-13 てんかんの治療 Expired - Fee Related JP6005357B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5410908P 2008-05-16 2008-05-16
US61/054,109 2008-05-16
PCT/US2009/043831 WO2009140416A2 (en) 2008-05-16 2009-05-13 Treatment for epilepsy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016109744A Division JP2016199553A (ja) 2008-05-16 2016-06-01 てんかんの治療

Publications (3)

Publication Number Publication Date
JP2011520900A JP2011520900A (ja) 2011-07-21
JP2011520900A5 true JP2011520900A5 (https=) 2012-06-14
JP6005357B2 JP6005357B2 (ja) 2016-10-12

Family

ID=41319319

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011509662A Expired - Fee Related JP6005357B2 (ja) 2008-05-16 2009-05-13 てんかんの治療
JP2016109744A Pending JP2016199553A (ja) 2008-05-16 2016-06-01 てんかんの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016109744A Pending JP2016199553A (ja) 2008-05-16 2016-06-01 てんかんの治療

Country Status (9)

Country Link
US (1) US9161965B2 (https=)
EP (1) EP2307035B1 (https=)
JP (2) JP6005357B2 (https=)
CN (1) CN102088990A (https=)
AU (1) AU2009246316B2 (https=)
CA (1) CA2724483C (https=)
DK (1) DK2307035T3 (https=)
ES (1) ES2446306T3 (https=)
WO (1) WO2009140416A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
US20140323924A1 (en) * 2013-04-26 2014-10-30 David J. Mishelevich Targeted optogenetic neuromodulation for treatment of clinical conditions
EP2950715A4 (en) * 2013-01-31 2016-11-30 Univ California SYSTEM AND METHOD FOR MODELING BRAIN DYNAMICS IN NORMAL AND ILLNESS STATES
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
US10583171B2 (en) 2015-11-30 2020-03-10 INSERM (Institut National de la Santé et de la Recherche Médicale) NMDAR antagonists for the treatment of diseases associated with angiogenesis
JP2019522675A (ja) * 2016-04-27 2019-08-15 ▲拝▼西欧斯(北京)生物技▲術▼有限公司 興奮製神経毒性に関連した損傷の治療方法
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
KR20250048151A (ko) * 2016-12-09 2025-04-07 알렉스자 파마스티칼즈, 인크. 간질 치료 방법
BR112020000115A2 (pt) 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
JP7073486B2 (ja) * 2017-09-30 2022-05-23 ▲拝▼西欧斯(北京)生物技▲術▼有限公司 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
CN111712252A (zh) 2017-12-13 2020-09-25 纽约州立大学研究基金会 用于治疗疼痛和提高疼痛敏感性的肽和其它药剂
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
EP3856212A1 (en) * 2018-09-27 2021-08-04 Finch Therapeutics Holdings LLC Compositions and methods for treating epilepsy and related disorders
US20210137853A1 (en) * 2019-09-17 2021-05-13 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US20050019841A1 (en) 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US20050282743A1 (en) 2001-08-03 2005-12-22 Arbor Vita Corporation Molecular interactions in cells
US20090075377A1 (en) 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
EP1709084A4 (en) 2003-12-23 2008-05-28 Nono Inc POLYPEPTIDES FOR MODULATING BINDING OF TRP-CHANNEL PROTEINS AND TRP-ASSOCIATED PROTEINS
WO2005097090A2 (en) * 2004-04-05 2005-10-20 Icos Corporation AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
CA2641421C (en) * 2005-12-30 2014-07-29 Arbor Vita Corporation Small molecule inhibitors of pdz interactions
US8633160B2 (en) 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
CN102088990A (zh) 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法

Similar Documents

Publication Publication Date Title
JP2011520900A5 (https=)
WO2008011174A3 (en) Jak inhibitors for treatment of myeloproliferative disorders
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
TWI371276B (en) Use of brimonidine for manufacture of a medicament for preventing or reducing severity of sensory hypersensitivity associated with migratine
MX2009012163A (es) Hetarilanilinas como moduladores para beta-amiloide.
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
IL201479A (en) Use of tapentadol for the preparation of pain medication
WO2011011186A3 (en) Hdac inhibitors and therapeutic methods using the same
JP2007523178A5 (https=)
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
MX2009012188A (es) Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos.
WO2009140416A3 (en) Treatment for epilepsy
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
MX2012003324A (es) Compuesto de glicina.
TR201814245T4 (en) USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS.
WO2008011083A3 (en) Compounds for enhancing arginase activity and methods of use thereof
JP2016501219A5 (https=)
WO2015079010A3 (en) Pharmaceutical composition comprising lacosamide and levetiracetam
WO2011034775A3 (en) Methods for treating brain tumors
EP2319521A4 (en) RAW MEDICINAL COMPOSITION FOR REGENERATION OF CARTILAGE, PAIN SUPPRESSION AND OENEM SUPPRESSION
WO2005089515A3 (en) Methods for the treatment of synucleinopathies
TW201129361A (en) Methods for treating pain
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
JP2009178162A5 (https=)